Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor

European Journal of Ophthalmology

Volumn 17, Issue 3, 2007, Pages 368-371

  Yalvac, Ilgaz Sagdic ^a,b,d   Basci, N E ^c   Dulger, B ^c   Duman, S ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d Cankaya 06690   (Turkey)

Author keywords

Aqueous humor; Betaxolol; Glaucoma; High performance liquid chromatography; Penetration

Indexed keywords

BETAXOLOL; BETOPTIC S; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE ANALYSIS; GLAUCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUSPENSION;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AQUEOUS HUMOR; BETAXOLOL; CATARACT EXTRACTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SUSPENSIONS;

EID: 34447136143     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700315     Document Type: Article

References (13)

1. Allen RC. Betaxolol in the treatment of glaucoma, multiclinic trials. Ophthalmology 1985; 91(Suppl): S142-7.
2. Dulger B, Basci NE, Yalvac IS, Temizer A. Determination of betaxolol in human aqueous humour by high-performance liquid chromatography with fluorescence detection. J Chromatogr B 2002; 772: 179-83.
3. Sharif NA, Xu SX. Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol and timolol at endogenous guinea pigs beta-adrenoreceptors. J Ocul Pharmacol Ther 2004; 20: 93-9.
4. Erkin EF, Celik P, Kayikcioglu O, Deveci HM, Sakar A. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica 2006; 220: 332-7.
5. Inan UU, Ermis SS, Orman A, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther 2004; 20: 293-310.
6. Ananthanarayan CR, Vaile SJ, Feldman F. Acute episode of asthma following topical administration of betaxolol eyedrops. Can J Ophthalmol 1993; 28: 80-1.
7. Weinreb RN, van Buskirk, Cherinack R, Drake MM. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol 1988; 106: 162-7.
8. Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Arch Ophthalmol 1983; 101: 898-900.
9. Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am J Ophthalmol 1985; 100: 777-82.
10. Weinreb RN, Jani R. A novel formulation of an ophthalmic beta-adrenoceptor antagonist. J Parenter Sci Technol 1992; 46: 51-3.
11. Yarangümeli A, Kural G. Are there any benefits of Betoptic® S (betaxolol HCl ophthalmic suspension) over other-blockers in the treatment of glaucoma? Exp Opin Pharmacother 2004; 5: 1071-81.
12. Weinreb RN, Caldwell DR, Goode SM, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.50% betaxolol ophthalmic solution. Am J Ophthalmol 1990; 110: 189-92.
13. Sacca SC, Marcia A, Rolando M, Ciurlo G. Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients. J Ocul Pharmacol Ther 1998; 14: 191-201.